Bayer Healthcare Resumes Production of Xofigo

November 6, 2014

Bayer Healthcare has resumed production of Xofigo® (radium Ra 223 dichloride). The initial lot of Xofigo has been released and is available to begin patient treatment this week.

"We are pleased to share that Bayer has resumed production of Xofigo," Bayer said in a Nov. 3 letter to healthcare professionals. "The initial lot of Xofigo has been released and is available to begin patient treatment this week. Bayer continues to work closely with the regulatory authorities to ensure that long-term supply is re-established as quickly as possible for patients."

In addition to the letter, Bayer shared an updated Q&A for prostate cancer patients receiving Xofigo therapy, including when therapy can be rescheduled, the impact of missed doses, and more about the problem that halted production.

Healthcare professionals and patients who have questions should contact Bayer Medical Affairs at 888-84-BAYER (1-888-842-2937).

November 11 Update: Bayer announced today that production of Xofigo for new patients will resume on Monday, November 17.